Sermorelin
GHRH analog that stimulates natural growth hormone release.
Key Benefits
triggers the pituitary to release growth hormone in its natural pulsatile pattern, unlike synthetic GH injections
research shows improved lean muscle mass and reduced fat mass over 3–6 month protocols
demonstrated increases in slow-wave (deep) sleep, the phase most critical for recovery and cellular repair
elevated GH and IGF-1 accelerate tissue repair, reduce recovery time between training sessions, and support joint health
Active Signaling Pathway
Sermorelin binds GHRH receptors on the pituitary, triggering pulsatile GH release that mirrors the body's natural nocturnal pattern. GH then travels systemically to stimulate IGF-1 production in the liver.
Investigated Pathways
Proposed Mechanism
Sermorelin is a 29-amino acid peptide corresponding to the first 29 amino acids of endogenous GHRH. It binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering a cAMP-mediated signaling cascade that results in GH synthesis and pulsatile release. Unlike exogenous GH, Sermorelin preserves the natural feedback loop via somatostatin.
Research Highlights
- FDA-approved (1997) for GH deficiency in children; well-characterized safety profile from clinical use
- Studies show 20–30% increase in IGF-1 levels in GH-deficient adults after 3–6 months of therapy
- Demonstrated improvements in sleep architecture (increased slow-wave sleep) in aging subjects
- Unlike direct GH administration, Sermorelin does not suppress endogenous GH axis — pituitary remains responsive
Human observational or open-label study data exists. Controlled trial data may be limited. Not a treatment recommendation.
For laboratory research only
All Research Systems →Human Body
Research begins at the whole-organism level — studying systemic metabolic markers, energy expenditure, and physiological response to peptide intervention.
For laboratory research and educational purposes only.
Human Body
Research begins at the whole-organism level — studying systemic metabolic markers, energy expenditure, and physiological response to peptide intervention.
For laboratory research and educational purposes only.
For research use only — not for human consumption. No treatment claims.
Full Research Hub →Recommended Stacks
Sermorelin is a key compound in these curated research stacks. Pair it with synergistic peptides for enhanced outcomes.
GH Pulse Amplifier
The gold-standard two-signal GH stack — CJC-1295 + Ipamorelin for maximum physiological GH output.
How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 5mg vial — and when to plan your next order.
Vial supply estimate is based on standard research protocol volumes. Actual duration will vary based on your specific protocol design.
Scientific Background
Mechanism of Action
Sermorelin is a 29-amino acid peptide corresponding to the first 29 amino acids of endogenous GHRH. It binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering a cAMP-mediated signaling cascade that results in GH synthesis and pulsatile release. Unlike exogenous GH, Sermorelin preserves the natural feedback loop via somatostatin.
Clinical Context
Sermorelin has one of the longest clinical track records of any GHRH analog. Its short half-life (~10–20 min) means it mimics the natural pulsatile pattern of GH release when dosed pre-sleep, aligning with the body's largest natural GH pulse. This physiological dosing pattern is considered superior to continuous GH elevation.
Research Highlights
- FDA-approved (1997) for GH deficiency in children; well-characterized safety profile from clinical use
- Studies show 20–30% increase in IGF-1 levels in GH-deficient adults after 3–6 months of therapy
- Demonstrated improvements in sleep architecture (increased slow-wave sleep) in aging subjects
- Unlike direct GH administration, Sermorelin does not suppress endogenous GH axis — pituitary remains responsive
Storage & Reconstitution
Key Studies
Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Walker RF et al.
Sermorelin stimulates pituitary GH release in a physiological pulsatile pattern, preserving the hypothalamic-pituitary feedback axis unlike exogenous GH.
PubMed →Sermorelin acetate: a review of its use in growth hormone deficiency
Prakash A et al.
Clinical review confirming sermorelin's efficacy and safety for GH deficiency with a well-characterized pharmacokinetic profile.
PubMed →Effects of sermorelin on body composition in healthy adults
Vittone J et al.
Sermorelin treatment improved lean body mass and reduced fat mass in healthy adults over 6 months with favorable safety profile.
PubMed →Pharmacokinetics
Bioavailability indicates how much of the compound reaches systemic circulation. Peak plasma is when blood levels are highest. Half-life determines dosing frequency — compounds with short half-lives require more frequent dosing to maintain therapeutic levels.
The volume of distribution reflects how widely the compound distributes into tissues. A higher Vd means the compound concentrates in tissues rather than staying in plasma.
Receptor Binding Profile
Triggers cAMP/PKA cascade in pituitary somatotrophs, stimulating GH synthesis and pulsatile release
Preserves natural somatostatin feedback loop — no axis suppression
Downstream hepatic IGF-1 production following GH pulse
Side Effects & Adverse Events
- Injection site redness and swelling
- Flushing
- Headache
- Dizziness
- Nausea
- Transient hyperactivity
- None documented at therapeutic doses
Contraindications & Interactions
Synergistic Compounds
GHRH + GHRP dual-signal mechanism produces 10× more GH than either peptide alone, closely mimicking physiological GH release.
Sermorelin 300 mcg + Ipamorelin 200 mcg in same syringe, SubQ pre-sleep.
View Compound →GH/IGF-1 elevation from sermorelin synergizes with BPC-157's tissue repair signaling for enhanced recovery outcomes.
Sermorelin 300 mcg pre-sleep + BPC-157 250 mcg AM, both SubQ.
View Compound →Both are GHRH analogs; CJC-1295 w/o DAC can substitute or rotate with sermorelin for pulsatile GH protocols.
Alternate sermorelin and CJC-1295 w/o DAC weekly to prevent receptor desensitization.
View Compound →Transparent Global Sourcing
Manufactured
Sourced through our manufacturing partner in China
Independent Testing
Analytical reports available from Janoshik Analytical
Batch Verification
Batch-specific COAs with online verification via janoshik.com
US Fulfillment
Orders fulfilled from the United States